• Mashup Score: 6

    ∗Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Blalock 524A, Baltimore, Maryland 21287, USA. E-mail: E-mail Address: [email protected] Published by Elsevier on Behalf of The American College of Cardiology Foundation. Published online April 12,

    Tweet Tweets with this article
    • Patients with Lp(a) ≥50 mg/dL and hsCRP ≥2 mg/L have nearly two-fold ⬆️risk of incident aortic valve calcification; potential #ACCPrev role for screening & risk stratification for valvular heart disease. https://t.co/zwm4ve9aiV #cvVHD #JACCIMG #CardioTwitter https://t.co/wZs6xI8kvz

  • Mashup Score: 3

    The gains come amid positive shifts for CRP and NT-proBNP, suggesting more than weight loss is at play, the PI says.

    Tweet Tweets with this article
    • Speaking to @TCTMD abt STEP HF, #ACCPrev Chair @DrEugeneYang was positive but cautioned, "On the other hand, from the perspective of risk-benefit & cost-effectiveness, this study doesn't address that." https://t.co/fRnz1T95nC #ESCCongress

    • RT @ShelleyWood2: 1/ Hot Line 1 trials on @TCTMD: STEP-HFpEF: Semaglutide Cuts Weight and Symptoms, Boosts Function https://t.co/LDWoRXnTL3